Kador Peter F, Salvi Richard
Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Center for Hearing and Deafness, University at Buffalo, Buffalo, New York, USA.
Antioxid Redox Signal. 2021 Aug 13;36(16-18):1136-57. doi: 10.1089/ars.2021.0129.
Oxidative stress contributes to vision, hearing and neurodegenerative disorders. Currently, no treatments prevent these disorders; therefore, there is an urgent need for redox modulators that can prevent these disorders. Oxidative stress is associated with the generation of reactive oxygen species (ROS) and reactive nitrogen species, metal dyshomeostasis, and mitochondrial dysfunction. Here, we discuss the role that oxidative stress and metal dyshomeostasis play in hearing loss, visual impairments, and neurodegeneration and discuss the benefits of a new class of multifunctional redox modulators (MFRMs) that suppress sensory and neural degeneration. MFRMs not only reduce free radicals but also independently bind transition metals associated with the generation of hydroxyl radicals. The MFRMs redistribute zinc from neurotoxic amyloid beta zinc (Aβ:Zn) complexes to the cytoplasm, facilitating the degradation of Aβ plaques by matrix metalloprotease-2 (MMP-2). Although MFRMs bind copper (Cu, Cu), iron (Fe, Fe), zinc (Zn), and manganese (Mn), they do not deplete free cytoplasmic Zn and they protect mitochondria from Mn-induced dysfunction. Oral administration of MFRMs reduce ROS-induced cataracts, protect the retina from light-induced degeneration, reduce neurotoxic Aβ:Zn plaque formation, and protect auditory hair cells from noise-induced hearing loss. Regulation of redox balance is essential for clinical efficacy in maintaining sensory functions. Future use of these MFRMs requires additional pharmacokinetic, pharmacodynamics, and toxicological data to bring them into widespread clinical use. Additional animal studies are also needed to determine whether MFRMs can prevent neurodegeneration, dementia, and other forms of vision and hearing loss.
氧化应激会导致视力、听力和神经退行性疾病。目前,尚无治疗方法可预防这些疾病;因此,迫切需要能够预防这些疾病的氧化还原调节剂。氧化应激与活性氧(ROS)和活性氮的产生、金属稳态失衡以及线粒体功能障碍有关。在此,我们讨论氧化应激和金属稳态失衡在听力损失、视力损害和神经退行性变中所起的作用,并探讨一类新型多功能氧化还原调节剂(MFRMs)在抑制感觉和神经退行性变方面的益处。MFRMs不仅能减少自由基,还能独立结合与羟基自由基产生相关的过渡金属。MFRMs将锌从神经毒性淀粉样β锌(Aβ:Zn)复合物重新分配到细胞质中,促进基质金属蛋白酶-2(MMP-2)对Aβ斑块的降解。尽管MFRMs能结合铜(Cu,Cu)、铁(Fe,Fe)、锌(Zn)和锰(Mn),但它们不会耗尽细胞质中的游离锌,并且能保护线粒体免受锰诱导的功能障碍。口服MFRMs可减少ROS诱导的白内障,保护视网膜免受光诱导的退行性变,减少神经毒性Aβ:Zn斑块的形成,并保护听觉毛细胞免受噪声诱导的听力损失。氧化还原平衡的调节对于维持感觉功能的临床疗效至关重要。这些MFRMs的未来应用需要更多的药代动力学、药效学和毒理学数据,以便将它们广泛应用于临床。还需要进行更多的动物研究,以确定MFRMs是否能够预防神经退行性变、痴呆以及其他形式的视力和听力损失。